SYNTHETICMR AB
0.55
SEK
-0.05
(-8.33%)
ISIN
SE0015987946
Return %
Stock
S&P 500
1Y
-73.79
14.20
3Y
-96.65
81.12
5Y
-98.96
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Lena Åredal
- Full Time Employees
- 38
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Linköping Sweden
- IPO Date
- Oct 18, 2013
- Website
- syntheticmr.com
- Similar Companies
- Business
- SyntheticMR AB is a Sweden-based medical technology company that develops and markets software solutions for quantitative magnetic resonance imaging (qMRI). Founded in 2007 and headquartered in Linköping, Sweden, the company specializes in analytical software tools that shorten MRI examination times, optimize radiology clinical workflows, and provide objective biomarker measurements for enhanced diagnostic precision. SyntheticMR AB serves hospitals, diagnostic imaging centers, academic research institutions, and medical device manufacturers globally, operating across Europe, North America, and the Asia-Pacific region with dedicated subsidiaries including SyntheticMR Inc. in the United States, SyntheticMR Japan GK in Japan, and SyntheticMR India Pvt Ltd in India. The company's primary business activity centers on its proprietary SyMRI software platform, which measures physical tissue properties and synthesizes multiple diagnostic contrast images from a single quantitative scan. The product suite includes: SyMRI NEURO, an automated post-processing application providing brain tissue segmentation, volumetric analysis, and myelin quantification alongside adjustable contrast images such as T1-weighted, T2-weighted, FLAIR, and STIR; SyMRI 3D, a high-resolution, three-dimensional quantitative imaging solution delivering isotropic voxel data for precise volumetric assessment of brain structures and lesion tracking; SyMRI MSK, a specialized application for musculoskeletal tissue characterization; SyMRI Research Edition, a dedicated platform offering exportable parametric maps of relaxation times (T1, T2) and proton density (PD) for clinical research; and OEM-embedded packages developed for integration into Picture Archiving and Communication Systems (PACS) and clinical review workstations. In recent developments, SyntheticMR AB has advanced its product portfolio and deepened strategic partnerships with leading global imaging equipment manufacturers. The company secured U.S. Food and Drug Administration (FDA) 510(k) clearance and European Medical Device Regulation (EU MDR) certification for its SyMRI 3D software. Furthermore, SyntheticMR expanded its strategic collaboration with Philips Healthcare to commercialize SmartQuant Neuro, an integrated solution combining Philips SmartSpeed acceleration with SyMRI 3D quantitative capabilities. The company also maintains ongoing OEM integration and distribution agreements with GE HealthCare (integrated under the MAGiC application), Siemens Healthineers (via the Syngo platform and Digital Marketplace), and Canon Medical Systems, reinforcing its international market penetration and expanding its clinical install base.